Dr Gesa Gnegel and Dr Céline Caillet’s presentation entitled ‘Choosing portable screening devices for the detection of substandard and falsified medicines - an online resource to guide national medicines regulators‘ (online resource named DAFODIL) was embedded in a session organized by the Association of Research-Based Pharmaceutical Companies (vfa), the Ecumenial Pharmaceutical Network (EPN) and the University of Tübingen, and chaired by Prof Lutz Heide of the University of Tübingen, Germany.
Find out more information about the DAFODIL online resource on the CGHR website
The session included further talks by
- Prof Raffaella Ravinetto of the Institute of Tropical Medicine in Antwerp, Belgium,
- Rutendo Kuwana the head of the WHO Incidents and Substandard/Falsified Medical Products unit,
- Prof Eliangiringa Kaale of the Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania, and
- Richard Neci the executive director of the Ecumenical Pharmaceutical Network (EPN), Kenya.
The talks were followed by a very interesting Questions & Answers and lots of interest for DAFODIL.
Over 3,500 participants were present at the World Health Summit and 21,000 participants also joined online.
During the Summit’s central event - the ‘Signature event’, countries from all over the world pledged a total amount of 1 billion US dollars to help WHO fulfil its ‘Health for All’ mandate (2025-2028), with the aims to prevent 40 million avoidable deaths caused by diseases over the next four years.